Today: 21 June 2026
Browse Category

Stock Market 6 February 2026

Several major companies saw notable share price movements and corporate developments during the holiday-shortened week leading up to and following the Juneteenth market closure. Fiserv insiders, including six top executives and board members, purchased nearly $1.72 million in shares at an average price of $49.55, though the stock closed lower at $47.86, with the insider basket down 3.4%. CoreWeave is set to join the Nasdaq-100, with its shares up 17.3% over the week, while Rocket Lab will also be added to the index. SpaceX dropped 3.56% to $185.00, with options suggesting significant volatility ahead and potential index changes or research updates expected Monday. Micron reached an all-time high, closing at $1,133.99, up 8.7%. Verizon fell 5.7% to $45.37 as new plans and fee cuts shifted focus to subscriber growth, with investors watching upcoming debt-settlement steps. Plug Power rose 7.55% to $2.85, with attention on cash, financing, and project monetization in the coming week. Nu shares slipped 1.4% to $12.71 but remained up for the week, with a $1 billion buyback in focus. Super Micro gained 10.37% to $30.66, with traders eyeing a $7 billion equity-linked deal. GE Vernova, Vertiv, and Eaton posted strong gains, while U.S. regulators gave grid operators 60 days to address rules for large electricity users. Bank of America closed at $56.20, with investors awaiting the Fed’s annual stress-test results. Amazon rose 2.9% to $244.39 ahead of Prime Day, and Apple finished just under $300, with questions about margin sustainability. Other notable moves included AMC up 21% for the week, SoFi up 8%, and Grab outperforming the Nasdaq Composite.
Shell stock today: Buyback holds after profit miss, but the shares are still on edge

Shell stock today: Buyback holds after profit miss, but the shares are still on edge

Shell shares rose 0.3% to 2,779 pence in early London trading Friday after a 3.4% drop on weak earnings. The company raised its quarterly dividend by 4% to $0.372 per share and kept its $3.5 billion buyback. Quarterly profit fell 11% to $3.3 billion, the lowest since early 2021. Investors are watching oil prices and the pending U.S. license for Shell’s Venezuela gas project.
6 February 2026
Keppel share price wobbles after special-dividend surge — what BN4 investors watch next

Keppel share price wobbles after special-dividend surge — what BN4 investors watch next

Keppel shares fell 0.2% to S$11.60 in Friday afternoon trading after a 6% surge the previous day, driven by strong FY2025 results and a special dividend announcement. The company reported a 29% rise in annual profit to S$1.02 billion and named former DBS chief Piyush Gupta as incoming chairman. Investors await the April 17 AGM and regulatory clearance for the delayed M1 sale. Dividends are set for payment on May 8.
SGX stock today: Singapore Exchange shares edge lower after record profit, broker lifts target

SGX stock today: Singapore Exchange shares edge lower after record profit, broker lifts target

Singapore Exchange Ltd reported record half-year adjusted net profit of S$357.1 million and raised its quarterly dividend to 11 cents per share. Shares slipped 0.2% to S$17.61 Friday as investors weighed the dividend hike against signs of slowing fee momentum. The exchange added 15 new equity listings in the six months to Dec. 31. Payment of the interim dividend is set for Feb. 24.
6 February 2026
OCBC share price slips in Singapore trade — what investors are watching before Feb 25 results

OCBC share price slips in Singapore trade — what investors are watching before Feb 25 results

OCBC shares fell 0.8% to S$21.28 by mid-afternoon Friday in Singapore, ahead of its Feb. 25 earnings report. Maybank Research expects flat to slightly weaker results for the bank, with investors watching for signs of easing pressure on net interest margins. OCBC also transferred 2,310 treasury shares for employee schemes, leaving 10.69 million treasury shares on its books.
Yangzijiang Shipbuilding shares slide 5% as Maersk warning jolts shipping-linked stocks

Yangzijiang Shipbuilding shares slide 5% as Maersk warning jolts shipping-linked stocks

Yangzijiang Shipbuilding shares fell about 5% to S$3.20 by Friday afternoon in Singapore, erasing over S$700 million in market value. The drop followed Maersk’s warning that lower freight rates and increased ship supply could hit earnings through 2026. Investors shifted focus to shipping-rate trends and Yangzijiang’s earnings due in March. Broader Singapore and Asian markets also declined.
6 February 2026
Xero share price ends lower as AI disruption fears keep ASX tech under pressure

Xero share price ends lower as AI disruption fears keep ASX tech under pressure

Xero shares closed down 0.4% at A$81.76 Friday after plunging 16% midweek, their steepest drop since 2013. The selloff followed fresh AI launches from Anthropic and investor concerns over software pricing power. Xero said over two million subscribers use its AI tools and expects Melio to reach breakeven in H2 FY28. WiseTech Global fell 4.7% as software stocks faced continued pressure.
Northern Star Resources (ASX:NST) share price drops 1.7% as $50m Tanami deal closes amid ASX rout

Northern Star Resources (ASX:NST) share price drops 1.7% as $50m Tanami deal closes amid ASX rout

Northern Star Resources shares fell 1.7% to A$26.77 Friday, with A$182 million traded, as gold miners and banks dragged the S&P/ASX 200 down 2%. MGX Resources completed a A$50 million purchase of a 50% stake in the Central Tanami Gold Project from Northern Star. Spot gold rose about 1% to $4,819 an ounce late in the session. Northern Star’s half-year results are due Feb. 12.

Stock Market Today

  • FDA Decisions Near for Achieve Life Sciences and Unicycive Therapeutics Amid Manufacturing Concerns
    June 21, 2026, 5:31 PM EDT. Achieve Life Sciences (NASDAQ: ACHV) shares dropped 9.51% to $4.85 following a June 20 FDA deadline tied to manufacturing issues likely leading to a Complete Response Letter (CRL). Unicycive Therapeutics (NASDAQ: UNCY) saw a 2.84% decline to $6.85 ahead of an FDA decision now expected by June 29, delayed from June 27. Both companies face regulatory reviews focusing on manufacturing compliance rather than drug efficacy. Achieve's cytisinicline showed strong Phase 3 efficacy with 32.4% abstinence vs. 6% placebo over 12 weeks, but manufacturing setbacks at a previous contract facility prompted a shift to Adare Pharma. Market reactions reflect uncertainty over remediation timelines rather than clinical data. Liquidity stands at about 39.7% and 31.2% of implied equity for ACHV and UNCY respectively, pressuring valuations as investors await regulatory outcomes.

Latest articles

Infosys drops after Accenture forecast adds to Indian IT pressure

Infosys stock heads into the week after Accenture news hits Nifty IT

21 June 2026
Infosys plunged 6.75% to ₹1,051.40 after Accenture cut its fiscal 2026 revenue growth outlook, triggering a sector-wide selloff that sent Nifty IT to a three-year low; investors are reassessing Indian IT stocks as hopes for a demand recovery fade, with analysts warning that slow growth and delayed client spending could keep valuations under pressure ahead of Infosys’ July 23 earnings.
Six Fiserv Insiders Bought $1.72M of NASDAQ: FISV Ahead of Holiday

Six Fiserv Insiders Bought $1.72M of NASDAQ: FISV Ahead of Holiday

21 June 2026
Six Fiserv insiders bought 34,781 shares for $1.72 million after CEO Mike Lyons’ abrupt exit, but FISV closed at $47.86—down 3.4% from their $49.55 average price and 10.9% since the leadership change—leaving the group with a $58,783 paper loss as the stock trades at just 5.8–6.0 times reaffirmed 2026 adjusted EPS guidance, with investors awaiting proof of a turnaround.
CoreWeave edges higher before Nasdaq-100 debut, week looks ahead to debt moves

CoreWeave stock moves up as it eyes Nasdaq-100 after 17% weekly gain

21 June 2026
CoreWeave will join the Nasdaq-100 before Monday’s open, triggering index fund buying tracked by over $800 billion in assets; shares closed Thursday at $117.95, up 17.3% in five days, as investors weigh AI infrastructure demand against heavy capital spending and a widened Q1 net loss of $740 million.
Go toTop